annual meeting header image

Industry Supported Education

2013 Industry Presentations

Symposia
Supported by Genentech

Breakfast Symposia
A Multidisciplinary Approach to Breast and Gastric Cancer Diagnoses: A Focus on HER2
Thursday, September 19, 2013
6:30—8:00 a.m.
Room—Crystal B
Presenter—Kenneth Bloom, MD, FCAP, Clarient, Inc., Aliso Viejo, CA

This program is targeted toward pathologists, lab directors, and individuals responsible for decision making about testing processes.

  • Provide background on the biology of HER2-driven disease
  • Offer insight on the importance of accurate HER2 testing and its potential impact on patients with breast cancer and gastric cancer
  • Educate pathologists and clinicians on ways to help ensure quality testing of HER2

Innovation Theater

QIAGEN: Your key to next generation molecular diagnostics
Wednesday, September 18, 2013
7:45—8:15 pm
Science Connection Central – Innovation Theater
Presenter: Belinda Yen-Lieberman, Ph.D.
Professor of Pathology, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University Pathology & Lab Medicine Institute, Cleveland Clinic, Cleveland, Ohio

QIAGEN has been enabling molecular discovery and, more recently, molecular diagnostics through technologies for the extraction and detection of nucleic acids (DNA and RNA) of target diseases or pathogens in samples such as blood, tissue and any other biologic sample type. These procedures can help detect viruses and bacteria more rapidly and with greater sensitivity and specificity than other methods. Molecular diagnostics are also used to analyze individual patient's genomic information to further classify certain diseases and to determine the most appropriate treatment. QIAGEN's portfolio in molecular diagnostics covers various applications, including Prevention, Profiling, Personalized Healthcare and Point of Need.

Dr. Yen-Lieberman & Cleveland Clinic pathology laboratories has used QIAGEN products since 1995, first with HPV by Hybrid Capture; and today her lab uses Quantitative CMV, EBV and BK viruses for monitoring  & managements of post-transplant patients,  HPV Hybrid Capture 2.0 test to screen women over 30 yrs old.  She will discuss how QIAGEN has supported the Cleveland Clinic's molecular diagnostic tests throughout the years.


The CLIA role of Laboratory Director: More than just a Title
Thursday, September 19, 2013
7:15—7:45 am
Science Connection Central—Innovation Theater
Presenter: Stacy Olea, MBA, MT(ASCP), FACHE
Field Director, The Joint Commission

No matter what type of CLIA certificate you have, being the laboratory director is more than just a title.  Learn the regulatory responsibilities that go along with the role as well as the expectations from an accrediting organization's perspective.


Integration with Clinical Systems for Scalable Workflows and Clinical-level Quality in the Molecular Lab
Wednesday, September 18, 2013
8:25—8:55 pm
Science Connection Central—Innovation Theater
Presenter: Megan Schmidt, Senior Product Manager, Sunquest Information Systems, Inc.

Description:  The advancements and trends in the molecular diagnostic testing market will peak your interest in your lab's adoption of new technology. Note key areas for evaluation when considering bringing molecular diagnostic testing into the lab. Gain insight into the handling of molecular diagnostics, like how in-house versus send out, and IT-LIS decisions can impact your quality of care and bottom line Learn how to achieve efficiency, manage inventory and achieve quality control for molecular diagnostics in facilities of various types and sizes.



Sharpening the Focus on Castleman's Disease: Better Strategies for Diagnosis and Management
Friday, September 20, 2013
12:30—2:15 pm
Crystal C, Green Level, West Tower
Faculty:
Frits van Rhee, MD, PhD, MRCP (UK), FRCPath, Professor of Medicine, Director of Clinical Research
Myeloma Institute for Research and Therapy, University of Arkansas Medical Sciences
Nikhil C. Munshi, MD Associate Professor of Medicine, Harvard Medical School, Associate Director, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute
David Wu, MD, PhD, Assistant Professor, University of Washington Hematopathology

Castleman’s disease (CD, angiofollicular lymph node hyperplasia) is a lymphoproliferative disorder that includes a wide spectrum of pathologic findings, manifestations, and associations. Although CD was discovered more than 5 decades ago, its pathophysiologic basis remained unknown until recently for which this new understanding of disease biology has informed effective drug development. Physicians as well as non-physician laboratory professionals must be well informed of the current state-of-the-art clinical and pathologic features of CD and the different entities that CD may mimic in order to aid in accurate diagnosis and ultimately improve patient care. The goal for this educational activity is to provide clinicians with the latest emerging evidence in Castleman's disease that can be applied in clinical practice to improve disease diagnosis and management and ultimately patient outcomes. The symposium will be designed specifically to reinforce key educational objectives and engage attendees in discussion. All attendees will be provided a knowledge assessment survey for completion.




Proposal Form and Submission Guidelines

Thank you for your interest in submitting a proposal for an educational session/activity at the 2013 ASCP Annual Meeting. Please submit a separate form for each proposed educational session or activity.

All proposals must be submitted via this form. Proposals received in any format other than this proposal form will not be reviewed by ASCP.

Availability of time and date slots for industry-supported education is limited and will be considered on a first-come basis. If multiple requests are made for the same time/date slot, then the date of receipt of each proposal by ASCP will be used to establish priority for slot assignments. If a desired date/time slot is not available, an alternate slot may be offered.

Proposals must be submitted in English and all information requested must be completed. Submission of a proposal does NOT guarantee acceptance of an educational session or activity at the 2013 ASCP Annual Meeting. ASCP will provide feedback to all proposal submissions in a timely manner, but will not identify the individual reviewers.

For details on the proposal submission and review process refer to Submission Guidelines.

Return completed proposals via email or fax to: Terri Berkowitz, ASCP, Manager, Professional Relations

Phone
In U.S.: 1-847-375-4763
Outside U.S.: +18473754763

Fax
In U.S.: 1-847-375-6459
Outside U.S.: +18473756459

Email: tberkowitz@connect2amc.com

Special thanks to our collaborating societies:

partners